TLN-4601
“These results highlight the ability of TLN-4601 to rapidly induce cell death in a hematologic tumor cell line and expand our understanding of TLN-4601 beyond its inhibition of the Ras MAPK signaling pathway,” said Lloyd M. Segal, Chief Executive Officer of Thallion. “Apoptotic pathways are validated molecular targets for new cancer therapeutics as apoptotic defects are commonly present in cancer cells. In this study, the differential sensitivity to TLN-4601 observed between a liquid tumor cell line and normal human blood lymphocytes suggests that further investigation in hematological malignancies is warranted.”